Bioventix
Research Bioventix (BVXP) on Bullrun: market cap GBX 8.62B, P/E 11.7, dividend yield 9.0%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBVXP
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 8.62B
- P/E11.7
- Dividend yield9.0%
- Financial periodFY2025
- RevenueGBP 13.12M
- Revenue growth-3.6%
- Net incomeGBP 7.58M
- Free cash flowGBP 7.01M
- Gross margin90.9%
Valuation Snapshot
latest market cap is GBX 8.62B; P/E is 11.7; dividend yield is 9.0%.
About Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment.
Frequently asked questions
What is Bioventix's market cap?
Bioventix's market capitalization is GBX 8.62B.
What is Bioventix's P/E ratio?
Bioventix's price-to-earnings (P/E) ratio is 11.7.
Does Bioventix pay a dividend?
Bioventix has a dividend yield of 9.0%.
What does Bioventix do?
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications;